Epidemiologic and viral predictors of antiretroviral drug resistance among persons living with HIV in a large treatment program in Nigeria
JournalAIDS Research and Therapy
PublisherBioMed Central Ltd.
MetadataShow full item record
AbstractBackground: Expanded access to combination antiretroviral therapy (cART) throughout sub-Saharan Africa over the last decade has remarkably improved the prognosis of persons living with HIV (PLWH). However, some PLWH experience virologic rebound after a period of viral suppression, usually followed by selection of drug resistant virus. Determining factors associated with drug resistance can inform patient management and healthcare policies, particularly in resource-limited settings where drug resistance testing is not routine. Methods: A case-control study was conducted using data captured from an electronic medical record in a large treatment program in Nigeria. Cases PLWH receiving cART who developed acquired drug resistance (ADR) and controls were those without ADR between 2004 and 2011. Each case was matched to up to 2 controls by sex, age, and education. Logistic regression was used estimate odds ratios (ORs) and 95% confidence intervals (CIs) for factors associated with ADR. Results: We evaluated 159 cases with ADR and 299 controls without ADR. In a multivariate model, factors associated with ADR included older age (OR = 2.35 [age 30-40 years 95% CI 1.29, 4.27], age 41 + years OR = 2.31 [95% CI 1.11, 4.84], compared to age 17-30), higher education level (secondary OR 2.14 [95% CI 1.1.11-4.13]), compared to primary and tertiary), non-adherence to care (OR = 2.48 [95% CI 1.50-4.00]), longer treatment duration (OR = 1.80 [95% CI 1.37-2.35]), lower CD4 count((OR = 0.95 [95% CI 0.95-0.97]) and higher viral load (OR = 1.97 [95% CI 1.44-2.54]). Conclusions: Understanding these predictors may guide programs in developing interventions to identify patients at risk of developing ADR and implementing prevention strategies. Copyright 2020 The Author(s).
KeywordAcquired drug resistance
HIV drug resistance testing
Low Middle Income Countries (LMICs)
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85079648026&doi=10.1186%2fs12981-020-0261-z&partnerID=40&md5=51ce0461d47e34ec05e461f9b81df51c; http://hdl.handle.net/10713/12126
- Predictors of first-line antiretroviral therapy failure among adults and adolescents living with HIV/AIDS in a large prevention and treatment program in Nigeria.
- Authors: Ndembi N, Murtala-Ibrahim F, Tola M, Jumare J, Aliyu A, Alabi P, Mensah C, Abimiku A, Quiñones-Mateu ME, Crowell TA, Rhee SY, Shafer RW, Gupta R, Blattner W, Charurat ME, Dakum P
- Issue date: 2020 Nov 3
- Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study.
- Authors: Inzaule SC, Hamers RL, Noguera-Julian M, Casadellà M, Parera M, Kityo C, Steegen K, Naniche D, Clotet B, Rinke de Wit TF, Paredes R, PanAfrican Studies to Evaluate Resistance.
- Issue date: 2018 Nov
- Long-Term Outcomes on Antiretroviral Therapy in a Large Scale-Up Program in Nigeria.
- Authors: Meloni ST, Chang CA, Eisen G, Jolayemi T, Banigbe B, Okonkwo PI, Kanki PJ
- Issue date: 2016
- Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
- Authors: Van Vaerenbergh K
- Issue date: 2001
- Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa.
- Authors: Boender TS, Hoenderboom BM, Sigaloff KC, Hamers RL, Wellington M, Shamu T, Siwale M, Labib Maksimos EE, Nankya I, Kityo CM, Adeyemo TA, Akanmu AS, Mandaliya K, Botes ME, Ondoa P, Rinke de Wit TF
- Issue date: 2015 Dec 1